Compare Jabil Inc (JBL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Neurocrine Biosciences Inc — how do they compare? Jabil Inc trades at $360.5 (market cap $37.37B), while Neurocrine Biosciences Inc trades at $157 (market cap $16.46B). The key difference: Jabil Inc is far larger — about 2.3× Neurocrine Biosciences Inc's market cap, and Jabil Inc pays a 0.09% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| JBL | NBIX | |
|---|---|---|
Market Cap | $37.37B | $16.46B |
Sector | Technology | Health |
52-Week High | $385.50 | $185.50 |
52-Week Low | $192.49 | $123.10 |
Enterprise Value | $39.90B | $16.48B |
Dividend Yield | 0.09% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
